{
    "ticker": "SXTP",
    "name": "Synta Pharmaceuticals Corp.",
    "description": "Synta Pharmaceuticals Corp. is a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for cancer. Founded in 2007, Synta is committed to transforming the treatment landscape for patients with cancer by leveraging its proprietary drug candidates and advanced drug discovery platforms. The company's lead product candidate, ganetespib, is a potent inhibitor of heat shock protein 90 (HSP90), which plays a critical role in the maturation and stability of several key oncogenic proteins. Synta's research emphasizes the importance of targeting the tumor microenvironment and developing therapies that can enhance the body\u2019s immune response against tumors. Synta aims to improve the quality of life for cancer patients through advancements in precision medicine and targeted therapies. The company\u2019s pipeline includes a range of compounds that are designed to address various types of cancer and are currently in different stages of clinical trials. With a team of experienced scientists and industry veterans, Synta is dedicated to bringing innovative cancer therapies to market and working closely with healthcare providers to ensure that patients have access to these potentially life-saving treatments.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Lexington, Massachusetts, USA",
    "founded": "2007",
    "website": "https://www.syntapharma.com",
    "ceo": "Kathy E. H. Chiu",
    "social_media": {
        "twitter": "https://twitter.com/SyntaPharma",
        "linkedin": "https://www.linkedin.com/company/synta-pharmaceuticals/"
    },
    "investor_relations": "https://www.syntapharma.com/investor-relations",
    "key_executives": [
        {
            "name": "Kathy E. H. Chiu",
            "position": "CEO"
        },
        {
            "name": "David R. Hyman",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Oncology Therapeutics",
            "products": [
                "Ganetespib",
                "Other HSP90 Inhibitors"
            ]
        }
    ],
    "seo": {
        "meta_title": "Synta Pharmaceuticals Corp. | Innovative Cancer Therapies",
        "meta_description": "Synta Pharmaceuticals Corp. is dedicated to developing innovative therapeutics for cancer, focusing on precision medicine and targeted therapies to improve patient outcomes.",
        "keywords": [
            "Synta Pharmaceuticals",
            "Cancer Treatment",
            "Biotechnology",
            "HSP90 Inhibitors",
            "Ganetespib"
        ]
    },
    "faq": [
        {
            "question": "What does Synta Pharmaceuticals specialize in?",
            "answer": "Synta Pharmaceuticals specializes in developing innovative therapeutics for cancer."
        },
        {
            "question": "Who is the CEO of Synta Pharmaceuticals?",
            "answer": "Kathy E. H. Chiu is the CEO of Synta Pharmaceuticals Corp."
        },
        {
            "question": "Where is Synta Pharmaceuticals headquartered?",
            "answer": "Synta Pharmaceuticals is headquartered in Lexington, Massachusetts, USA."
        },
        {
            "question": "What is Synta's lead product candidate?",
            "answer": "Synta's lead product candidate is ganetespib, a potent HSP90 inhibitor."
        },
        {
            "question": "When was Synta Pharmaceuticals founded?",
            "answer": "Synta Pharmaceuticals was founded in 2007."
        }
    ],
    "competitors": [
        "CLVS",
        "NDAQ",
        "EXEL",
        "SNY"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "CELG",
        "BMY"
    ]
}